Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by toinv261on Nov 21, 2015 5:08pm

170 Views

Post# 24312831

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:The Agoracom board!!!! ,,,, Hmmmmmmmmmm!!

Hey jdstox.

I sure agree with you. I have been very critical of Don over the years but he is making it happen and he's done it for 15 years. That is a remarkable achievement and I wish I personally had 1/3rd of his achievements.

I am a firm believer in the epigenetic science of rvx-208 and the epigenetic portfolio of solid tumour and haematological treatment drugs at Zenith.

However, here are a few (I think minor but real) things that make investors suspicious;

The promise of a Zenith IPO on NASDAQ for Q4 2015 and the lack of a pre-emptive statement on this (better tell us than leave us in the dark).
Until the past year communications have been poor and communications is still not optimal.
Don's double dipping as CEO of both RVX and Zenith. If he hires a new Zenith CEO I expect to see his $900,000 drop to $500,000 compensation.
A general pattern of Don making flippant remarks (seems to have reduced recently but the history is there).

So these are minor points.

With BETonMACE we can sit back and relax until late 2018. In the interim we may see;